APA (7th ed.) Citation

I, K., P, M., J, G., A, P., P, S., K, V., . . . NH, T. (2025). First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: A real world, multicenter retrospective study. The oncologist, 30(11), . https://doi.org/10.1093/oncolo/oyaf286

Chicago Style (17th ed.) Citation

I, Kournoutas, et al. "First-line Atezolizumab/bevacizumab or Durvalumab/tremelimumab in Advanced Hepatocellular Carcinoma: A Real World, Multicenter Retrospective Study." The Oncologist 30, no. 11 (2025). https://doi.org/10.1093/oncolo/oyaf286.

MLA (9th ed.) Citation

I, Kournoutas, et al. "First-line Atezolizumab/bevacizumab or Durvalumab/tremelimumab in Advanced Hepatocellular Carcinoma: A Real World, Multicenter Retrospective Study." The Oncologist, vol. 30, no. 11, 2025, https://doi.org/10.1093/oncolo/oyaf286.